Ian Somaiya is the new CFO of NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) has announced the appointment of Ian Somaiya as Chief Financial Officer. Mr. Somaiya is a healthcare executive with significant financial and operational expertise, including over twenty years of experience as a prominent biotechnology research analyst on Wall Street.

Mr. Somaiya comes to NewAmsterdam Pharma with over twenty-five years of experience in senior leadership roles in the biopharmaceutical industry. Most recently, he served as CFO and Chief Business Officer of Elucida Oncology and, prior to that, as CFO of TCR2 Therapeutics, where he managed the company through its initial public offering and subsequent follow-on offerings and oversaw the finance, reporting business development, and investor relations functions. Before joining TCR2, Mr. Somaiya was the managing director and head of biotechnology research at BMO Capital Markets. He also held roles as managing director and equity analyst at Nomura Securities, Piper Jaffray, and Thomas Weisel Partners.

His career began as a research analyst at Morgan Stanley and Prudential Securities on Wall Street. During his two-decade tenure on Wall Street, Mr. Somaiya was a highly regarded industry equity analyst known for his comprehensive research on over 100 biotechnology companies spanning diverse therapeutic areas, technology platforms, and development stages. Mr. Somaiya holds a B.A. in Biology and Neuroscience from New York University.

Have you read?
The World’s Top 10 Highest-Paid Wealth Management Executives.
CEO compensation: Highest paid chief executive officers in the United States in 2022.
Highly-Paid Entertainment Chief Executives (Averaged $31.66 Million), 2022.
Highest paid health insurance CEOs.
Most Powerful Companies in Australia, 2023.